Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07536061) titled 'A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease' on April 10.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: Sarepta Therapeutics, Inc.
Condition:
Huntington's Disease
Intervention:
Drug: SRP-1005
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: May 5, 2026
Target Sample Size: 32
Countries of Recruitment:
New Zealand
To know more, visit https://clinicaltrials.gov/study/...